Structural heart specialist Transmural Systems strengthens board as it prepares for rapid growth

Andover, MA - Transmural Systems, the leader in transcatheter electrosurgery for structural heart failure, has announced two Board-level appointments: Jeffrey B. Jump as Executive Chairman and Simos Kedikoglou as Board Director. Both of these individuals have many years’ experience in the medical device industry, specializing in the cardiovascular sector.

“I am pleased to welcome both Jeff and Simos, who will help us focus on accelerating growth by executing new strategies to expand structural heart procedures and benefit patients around the world”, said Nasser Rafiee, CEO and Founder of Transmural Systems.

Jeff was most recently Chairman and CEO of MedAlliance, acquired by Cordis last October, and former CEO of Biosensors where he spent 15 years. Jeff has been chairman or board member of 15 companies, resulting in three IPOs and seven trade sales, including Symetis in the TAVR space. Simos was the CEO of Impulse Dynamics, a heart failure company, and a board member of MedAlliance; previously Simos was the Corporate Vice President, Business Development at Boston Scientific.

“I have been impressed by the unique platform of structural heart and electrosurgical therapies that Transmural Systems has developed.  They have positioned themselves to provide interventional cardiologists with the opportunity to treat many more patients that would have otherwise required complicated surgical or medical interventions. Over the past 10 years, Nasser, in collaboration with a team of pioneering structural heart failure physicians and engineers, has created innovative, disruptive, intuitive, safe and effective therapies for the structural heart space”, commented Jeff, expressing his excitement in joining Transmural.

Transmural has developed three significant structural heart platforms:

• TELLTALE - A simple, safe and effective interventional tool for leaflet modification. TELLTALE has received FDA Breakthrough designation, aiming to expand patient access for aortic and mitral valve procedures.  The first US TELLTALE clinical trial is nearly fully enrolled and is expected to undergo FDA review early next year.  
• SESAME - is a first-in-class transcatheter myotomy system, avoiding open heart surgery and a lifetime of expensive pharmacology.  SESAME addresses an important unmet need for hypertrophic cardiomyopathy (HCM) and to manage left ventricular flow obstruction. SESAME is a simple procedure that can be performed by every interventional cardiologist in cath labs around the globe.
• MIRTH - A myocardial intramural remodeling ventriculoplasty system that narrows the left ventricle circumferentially using controlled intramyocardial navigation to treat heart failure with reduced ejection fraction (HFrEF). 

Source: Transmural

^{This Industry Press Release does not reflect the opinion of PCR, nor does it engage its responsibility.}